Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × Sunitinib × 1 year × Clear all

Sponsor

Conditions

Carcinoma, Renal Cell 16 Gastrointestinal Stromal Tumors 7 Neoplasms 4 Multiple Myeloma 3 Kidney Neoplasms 3 Urologic Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Meningioma 2 Lymphoma, Non-Hodgkin 2 Kidney Diseases 2 Gastrointestinal Neoplasms 2 Carcinoma 2 Adenoma, Islet Cell 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thymoma 1 Thoracic Neoplasms 1 Somatostatinoma 1 Solid Tumors Refractory to Standard Therapy 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Prostatic Neoplasms 1 Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1 Pelvic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Nervous System Neoplasms 1

Interventions

fludarabine 4 Cisplatin 4 Pemetrexed 3 Cyclophosphamide 3 pralsetinib 2 pembrolizumab 2 fludarabine phosphate 2 durvalumab 2 cobimetinib 2 atezolizumab 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Paclitaxel 2 Nivolumab 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Busulfan 2 130-nm albumin-bound paclitaxel 2 trametinib 1 spartalizumab 1 ruxolitinib 1 repotrectinib 1 ponatinib 1 pertuzumab 1 gilteritinib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡